Murtazaeva Zarifa, Nasrullaev Azizbek, Buronov Anvarjon, Gaybullaev Shukhrat, Nie Lifei, Numonov Sodik, Khushnazarov Zohidjon, Turgunov Davron, Kuryazov Rustamkhon, Zhao Jiangyu, Bozorov Khurshed
Department of Organic Synthesis and Bioorganic Chemistry, Institute of Biochemistry, Samarkand State University, University Blvd. 15, Samarkand 140104, Uzbekistan.
State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, South Beijing Rd 40-1, Urumqi 830011, China.
Molecules. 2025 May 21;30(10):2245. doi: 10.3390/molecules30102245.
Imidazole is a five-membered heterocyclic system featuring two nitrogen heteroatoms at the 1- and 3-positions of the ring. The imidazole scaffold is particularly suited for kinase inhibition concepts. This further confirms that this scaffold is a privileged structure in the development of anticancer drugs. Considering these key factors and the recent focus of scientists on imidazole compounds, we discuss the anticancer activities of imidazole-containing hybrids and related compounds, highlighting articles published in 2023 that serve as a basis for medicinal chemistry leads. From a chemical perspective, the present review emphasizes hybrid molecules with an imidazole ring in the side chain, imidazole-centered hybrid molecules, condensed imidazole hybrids, hybrid compounds containing two or more imidazole rings, polycyclic imidazole hybrids, imidazole-containing metal complexes, and benzimidazole hybrids.
咪唑是一种五元杂环体系，在环的1位和3位有两个氮杂原子。咪唑骨架特别适合激酶抑制概念。这进一步证实了该骨架在抗癌药物开发中是一种优势结构。考虑到这些关键因素以及科学家近期对咪唑化合物的关注，我们讨论了含咪唑杂化物及相关化合物的抗癌活性，重点介绍了2023年发表的作为药物化学先导基础的文章。从化学角度来看，本综述重点关注侧链带有咪唑环的杂化分子、以咪唑为中心的杂化分子、稠合咪唑杂化物、含有两个或更多咪唑环的杂化化合物、多环咪唑杂化物、含咪唑金属配合物以及苯并咪唑杂化物。
